Your session is about to expire
← Back to Search
PBF-1129 for Non-Small Cell Lung Cancer
Study Summary
This trial is testing a new compound to treat lung cancer. The goal is to find out if it is safe and how well it works.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any serious illnesses or infections that would stop me from receiving the study treatment.I have brain metastases that are either treated and stable or untreated and not worsening.You have a disease that can be measured using a specific set of guidelines.My lung cancer is confirmed to be metastatic through testing.I have an autoimmune disorder.I am taking 10mg or more of prednisone daily or its equivalent.I stopped smoking at least a week ago.I am fully active or restricted in physically strenuous activity but can do light work.I have had multiple treatments for my condition.My cancer has worsened despite standard treatments, including those for specific mutations.I am older than 18 years.I have not had an autoimmune disease in the past 2 years, except for vitiligo, Grave's disease, or psoriasis not needing systemic treatment.My kidney, liver, and bone marrow are functioning well.I have not had any other cancer in the past 2 years.I am not pregnant, breastfeeding, nor planning to become pregnant during the study.
- Group 1: PBF-1129_160mg
- Group 2: PBF-1129_320mg
- Group 3: PBF-1129_80mg
- Group 4: PBF-1129_40mg
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the application process for this research project still open?
"The clinical trial is recruiting, as evidenced by the data hosted on clinicaltrials.gov; it was first posted on October 1st 2018 and has since been updated twice - most recently done in February 22nd 2022."
Can you shed some light on the potential risks of PBF-1129?
"PBF-1129's safety rating is pegged at 1, as this is an early stage clinical trial with little evidence of the drug's efficacy and limited data on its safety."
What is the upper limit for enrollees in this investigation?
"Affirmative. According to information sourced from clinicaltrials.gov, this medical study is actively recruiting participants; it was initially posted on October 1st 2018 and the latest update occurred on February 22nd 2022. The trial requires 18 volunteers that can be found in a single location."
Share this study with friends
Copy Link
Messenger